Kura Oncology reports positive phase 2 study of tipifarnib in CML
Immune Design reports data from the randomized Phase 2 trial of its investigational intratumoral TLR4 agonist G100 plus low-dose radiation (G100 Monotherapy) with or without KEYTRUDAź (pembrolizumab), Merck's anti-PD-1 therapy, in follicular non-Hodgkin's lymphoma patients. December 10, 2017